Astec LifeSciences quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	72.0	73.7	−2.3%
EBITDA	−19.8	−6.7	—
EBITDA margin	−27.5%	−9.1%	−18.4 pts
Profit before tax	−37.4	−24.4	—
Net profit	−37.4	−24.4	—
EPS	−₹16.79	−₹11.35	—

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	72.0	83.6	159	125	73.7	91.1	120	93.9	98.5	69.4	154	50.8	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	0.6	0.7	2.6	0.8	1.1	0.5	0.8	1.9	2.0	0.9	2.0	0.9
	72.6	84.3	161	126	74.8	91.6	120	95.8	101	70.3	156	51.7
	56.3	76.3	71.3	81.7	58.1	59.4	85.5	63.3	66.4	33.7	82.5	43.2
	−4.0	−33.7	39.1	1.3	−16.8	4.5	−11.9	−1.7	13.8	47.9	22.8	−7.9
	15.1	16.0	16.3	15.8	15.6	15.2	14.4	15.5	14.9	16.2	14.7	14.4
	7.1	7.7	7.9	7.2	8.4	11.0	10.4	9.9	9.3	7.0	6.7	6.1
	11.2	11.1	11.8	11.2	10.4	11.5	11.6	11.4	11.5	9.3	9.0	8.7
	24.5	25.6	22.8	22.0	23.5	23.0	26.0	22.5	23.1	17.8	21.0	19.4
	110	103	169	139	99.2	125	136	121	139	132	157	83.9
	−19.8	−0.7	9.2	4.0	−6.7	−11.0	5.5	−5.7	−19.7	−46.3	12.7	−18.3
	−31.0	−11.7	−2.6	−7.2	−17.1	−22.5	−6.1	−17.1	−31.2	−55.5	3.7	−27.0
Profit
	−37.4	−18.7	−7.9	−13.6	−24.4	−33.0	−15.7	−25.1	−38.5	−61.6	−0.9	−32.2
	0.0	0.0	0.0	−2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	−37.4	−18.7	−7.9	−15.7	−24.4	−33.0	−15.7	−25.1	−38.5	−61.6	−0.9	−32.2
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	−0.0	−0.0	−0.2	0.0	0.0	−0.0	0.4	15.2	−0.0	−21.9	0.0	−7.9
	−0.0	−0.0	−0.2	0.0	0.0	0.0	0.4	15.2	0.0	−21.9	0.0	−7.9
	−37.4	−18.7	−7.7	−15.7	−24.4	−33.0	−16.1	−40.4	−38.5	−39.7	−1.0	−24.3
	−37.4	−18.7	−7.7	−15.7	−24.4	−33.0	−16.1	−40.4	−38.5	−39.7	−1.0	−24.3
	0.1	0.1	0.2	0.1	0.1	0.1	−0.2	0.0	0.4	0.0	−0.6	−0.0
	−37.3	−18.6	−7.5	−15.5	−24.4	−33.0	−16.3	−40.4	−38.1	−39.7	−1.5	−24.3
	−37.4	−18.7	−7.8	−15.7	−24.4	−33.0	−16.1	−40.4	−38.6	−39.7	−1.0	−24.3
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Per share
	−₹16.79	−₹8.40	−₹3.48	−₹7.04	−₹11.35	−₹16.85	−₹8.20	−₹20.59	−₹19.66	−₹20.26	₹0.50	−₹12.41
	−₹16.79	−₹8.40	−₹3.48	−₹7.04	−₹11.34	−₹16.85	−₹8.20	−₹20.59	−₹19.66	−₹20.26	₹0.50	−₹12.41
Other comprehensive income — detail
	0.1	0.1	0.2	0.1	0.1	0.1	−0.2	—	—	—	—	—
	0.2	0.2	0.4	0.1	0.1	0.1	−0.2	0.0	0.4	−0.0	−0.7	−0.0
	0.0	0.0	0.2	0.0	0.0	0.0	0.1	—	—	—	—	—
	—	—	—	—	—	—	—	0.0	0.0	−0.0	−0.2	−0.0
	−0.0	−0.0	—	—	—	−0.0	—	—	—	0.0	0.0	−0.0
	0.0	0.0	—	0.0	—	0.0	0.0	—	—	—	—	—
	−37.3	−18.6	−7.5	−15.6	−24.4	−33.0	−16.3	−40.4	−38.2	−39.7	−1.5	−24.3
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Per share — as-filed variants
	−₹16.79	−₹8.40	−₹3.48	−₹7.04	−₹11.35	−₹16.85	−₹8.20	−₹20.59	−₹19.66	−₹20.26	₹0.50	−₹12.41
	−₹16.79	−₹8.40	−₹3.48	−₹7.04	−₹11.34	−₹16.85	−₹8.20	−₹20.59	−₹19.66	−₹20.26	₹0.50	−₹12.41
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	19.8	40.9	48.3	41.8	32.4	27.2	46.0	32.3	18.3	−12.2	48.4	15.5
	27.5%	49.0%	30.4%	33.5%	44.0%	29.9%	38.5%	34.4%	18.6%	−17.6%	31.5%	30.5%
Adjusted (ex-exceptional items) — derived
	−37.4	−18.7	−7.9	−13.6	−24.4	−33.0	−15.7	−25.1	−38.5	−61.6	−0.9	−32.2
	0.0	0.0	0.0	−2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	−37.4	−18.7	−7.7	−13.6	−24.4	−33.0	−16.1	−40.4	−38.5	−39.7	−1.0	−24.3
	−₹16.79	−₹8.40	−₹3.48	−₹6.10	−₹11.35	−₹16.85	−₹8.20	−₹20.59	−₹19.66	−₹20.26	₹0.50	−₹12.41

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ASTEC₹581.05

Astec LifeSciences Limited

· Chemicals

Annual Quarterly₹ CrorePeersPUNJABCHEM MOL IPL INSECTICID DHARMAJ BHARATRAS ADVANCE HERANBAMcap ₹1,295 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	50.8	153.7	69.4	98.5	93.9	119.5	91.1	73.7	124.7	158.6	83.6	72.0
Other Income	0.9	2.0	0.9	2.0	1.9	0.8	0.5	1.1	0.8	2.6	0.7	0.6
Total Income	51.7	155.8	70.3	100.5	95.8	120.3	91.6	74.8	125.5	161.3	84.3	72.6
Expenses
+ Cost of Materials Consumed	43.2	82.5	33.7	66.4	63.3	85.5	59.4	58.1	81.7	71.3	76.3	56.3
+ Changes in Inventories	-7.9	22.8	47.9	13.8	-1.7	-11.9	4.5	-16.8	1.3	39.1	-33.7	-4.0
+ Employee Benefit Expense	14.4	14.7	16.2	14.9	15.5	14.4	15.2	15.6	15.8	16.3	16.0	15.1
+ Finance Costs	6.1	6.7	7.0	9.3	9.9	10.4	11.0	8.4	7.2	7.9	7.7	7.1
+ Depreciation & Amortisation	8.7	9.0	9.3	11.5	11.4	11.6	11.5	10.4	11.2	11.8	11.1	11.2
+ Other Expenses	19.4	21.0	17.8	23.1	22.5	26.0	23.0	23.5	22.0	22.8	25.6	24.5
Total Expenses	83.9	156.7	131.9	139.1	120.9	136.0	124.6	99.2	139.1	169.2	103.0	110.1
EBITDA	-18.3	12.7	-46.3	-19.7	-5.7	5.5	-11.0	-6.7	4.0	9.2	-0.7	-19.8
EBIT	-27.0	3.7	-55.5	-31.2	-17.1	-6.1	-22.5	-17.1	-7.2	-2.6	-11.7	-31.0
Profit
PBT before Exceptional Items	-32.2	-0.9	-61.6	-38.5	-25.1	-15.7	-33.0	-24.4	-13.6	-7.9	-18.7	-37.4
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1	0.0	0.0	0.0
Pretax Income	-32.2	-0.9	-61.6	-38.5	-25.1	-15.7	-33.0	-24.4	-15.7	-7.9	-18.7	-37.4
+ Current Tax	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Deferred Tax	-7.9	0.0	-21.9	-0.0	15.2	0.4	-0.0	0.0	0.0	-0.2	-0.0	-0.0
Tax Expense	-7.9	0.0	-21.9	0.0	15.2	0.4	0.0	0.0	0.0	-0.2	-0.0	-0.0
Net Income	-24.3	-1.0	-39.7	-38.5	-40.4	-16.1	-33.0	-24.4	-15.7	-7.7	-18.7	-37.4
+ Net Income — Continuing Ops	-24.3	-1.0	-39.7	-38.5	-40.4	-16.1	-33.0	-24.4	-15.7	-7.7	-18.7	-37.4
+ Other Comprehensive Income	-0.0	-0.6	0.0	0.4	0.0	-0.2	0.1	0.1	0.1	0.2	0.1	0.1
Total Comprehensive Income	-24.3	-1.5	-39.7	-38.1	-40.4	-16.3	-33.0	-24.4	-15.5	-7.5	-18.6	-37.3
Net Income to Common	-24.3	-1.0	-39.7	-38.6	-40.4	-16.1	-33.0	-24.4	-15.7	-7.8	-18.7	-37.4
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Per Share
Basic EPS	-12.41	0.50	-20.26	-19.66	-20.59	-8.20	-16.85	-11.35	-7.04	-3.48	-8.40	-16.79
Diluted EPS	-12.41	0.50	-20.26	-19.66	-20.59	-8.20	-16.85	-11.34	-7.04	-3.48	-8.40	-16.79
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	-0.2	0.1	0.1	0.1	0.2	0.1	0.1
+ Items NOT to be Reclassified to P&L	-0.0	-0.7	-0.0	0.4	0.0	-0.2	0.1	0.1	0.1	0.4	0.2	0.2
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	0.1	0.0	0.0	0.0	0.2	0.0	0.0
+ Tax on Items NOT to be Reclassified — alt tag	-0.0	-0.2	-0.0	0.0	0.0	—	—	—	—	—	—	—
+ Items to be Reclassified to P&L	-0.0	0.0	0.0	—	—	—	-0.0	—	—	—	-0.0	-0.0
+ Tax on Items to be Reclassified	—	—	—	—	—	0.0	0.0	—	0.0	—	0.0	0.0
Comprehensive Income — Owners of Parent	-24.3	-1.5	-39.7	-38.2	-40.4	-16.3	-33.0	-24.4	-15.6	-7.5	-18.6	-37.3
Comprehensive Income — Non-controlling Interests	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	-12.41	0.50	-20.26	-19.66	-20.59	-8.20	-16.85	-11.35	-7.04	-3.48	-8.40	-16.79
Diluted EPS — Continuing Operations	-12.41	0.50	-20.26	-19.66	-20.59	-8.20	-16.85	-11.34	-7.04	-3.48	-8.40	-16.79
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	15.5	48.4	-12.2	18.3	32.3	46.0	27.2	32.4	41.8	48.3	40.9	19.8
Gross Margin %	30.47	31.49	-17.61	18.59	34.39	38.48	29.86	44.00	33.52	30.44	49.00	27.48
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-32.2	-0.9	-61.6	-38.5	-25.1	-15.7	-33.0	-24.4	-13.6	-7.9	-18.7	-37.4
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.1	0.0	0.0	0.0
Net Income Adj (tax-effected)	-24.3	-1.0	-39.7	-38.5	-40.4	-16.1	-33.0	-24.4	-13.6	-7.7	-18.7	-37.4
EPS Adj	-12.41	0.50	-20.26	-19.66	-20.59	-8.20	-16.85	-11.35	-6.10	-3.48	-8.40	-16.79
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	—	10.00	10.00	10.00	10.00	10.00	10.00
Filed Debt Equity	1.00	1.00	2.00	2.00	2.00	—	2.95	0.89	1.08	—	0.98	0.99
Filed Dscr	0.00	1.00	-2.00	-1.00	-2.00	—	-0.21	-0.05	0.37	—	0.01	-1.11
Filed Iscr	-2.00	2.00	-3.00	-2.00	-2.00	—	-0.95	-0.66	0.38	—	0.03	-2.71
Paid Up Equity Capital	19.6	19.6	19.6	19.6	19.6	—	19.6	22.3	22.3	22.3	22.3	22.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Astec LifeSciences Q2 FY27 results (July–September 2026)

Filed with NSE on Monday, 26 October 2026 at 4:51 pm IST

Astec LifeSciences (NSE: ASTEC) reported its Q2 FY27 results (July–September 2026) on Monday, 26 October 2026 at 4:51 pm IST. Consolidated net loss was ₹37.4 crore, wider than the loss of ₹24.4 crore in Q2 FY26 and wider than the loss of ₹18.7 crore in Q1 FY27. Revenue from operations was ₹72 crore, down 2.3% year on year and down 13.8% from the previous quarter.

Q2 FY26 results (a year earlier): 29 October 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net loss: −₹37.4 Crloss ₹24.4 Cr in Q2 FY26loss ₹18.7 Cr in Q1 FY27
Revenue from operations: ₹72 Cr−2.3% vs Q2 FY26−13.8% vs Q1 FY27
Operating margin (EBIT): −43.0%−19.8 pts vs Q2 FY26−29.0 pts vs Q1 FY27EBIT −₹31 Cr
EBITDA: −₹19.8 Cr−₹6.7 Cr in Q2 FY26−₹67 lakh in Q1 FY27margin −27.5%
Earnings per share (basic): −₹16.79
Net profit margin: −51.9%−18.8 pts vs Q2 FY26−29.5 pts vs Q1 FY27

Questions

What was Astec LifeSciences' net profit in Q2 FY27?

Consolidated net loss was ₹37.4 crore, wider than the loss of ₹24.4 crore in Q2 FY26 and wider than the loss of ₹18.7 crore in Q1 FY27.

How were Astec LifeSciences' Q2 FY27 results?

A net loss of ₹37.4 crore, wider than the loss of ₹24.4 crore in Q2 FY26. Revenue was down 2.3% at ₹72 crore. The operating margin was −43.0%, down 19.8 percentage points from −23.2% a year earlier.

What is Astec LifeSciences' net profit margin?

Astec LifeSciences' net profit margin was −51.9% in Q2 FY27 (net profit as a share of revenue from operations), against −33.1% in Q2 FY26 (down 18.8 percentage points). For FY26 as a whole it was −18.1%.

What was Astec LifeSciences' revenue in Q2 FY27?

Revenue from operations was ₹72 crore, down 2.3% year on year and down 13.8% from the previous quarter.

What was Astec LifeSciences' EPS in Q2 FY27?

Basic earnings per share were −₹16.79, against −₹11.35 in Q2 FY26.

What was Astec LifeSciences' revenue in FY26?

Revenue from operations was ₹448 crore in FY26 (April 2025–March 2026), up 17.5% from ₹381 crore in FY25. It was ₹458 crore in FY24 and ₹628 crore in FY23: down 28.7% over three years, an average fall of 10.6% a year.

What was Astec LifeSciences' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was −₹31 crore, a margin of −43.0%, against −14.0% in Q1 FY27 and −23.2% in Q2 FY26. EBITDA was −₹19.8 crore, −27.5% of revenue.

What was Astec LifeSciences' net profit in the first half of FY27?

Consolidated net loss for the first half of FY27 (April–September 2026) was ₹56.1 crore, narrower than the loss of ₹57.5 crore in the same months a year earlier. Revenue from operations was ₹156 crore, down 5.6%.

How has Astec LifeSciences' profit changed over the last four quarters?

Net profit by quarter: a loss of ₹15.7 crore in Q3 FY26, a loss of ₹7.8 crore in Q4 FY26, a loss of ₹18.7 crore in Q1 FY27 and a loss of ₹37.4 crore in Q2 FY27. That is a combined loss of ₹79.6 crore over the four quarters. Revenue from operations: ₹125 crore, ₹159 crore, ₹83.6 crore and ₹72 crore.

What was Astec LifeSciences' net profit in FY26?

Consolidated net profit was a loss of ₹80.9 crore in FY26 (April 2025–March 2026), narrower than the loss of ₹135 crore in FY25. It was a loss of ₹46.9 crore in FY24 and a profit of ₹25.6 crore in FY23.

When did Astec LifeSciences announce its Q2 FY27 results?

On Monday, 26 October 2026 at 4:51 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 29 October 2025.

When will Astec LifeSciences announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Astec LifeSciences figures come from?

From Astec LifeSciences' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 26 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.